Isabelle Lavenu
A5006797643- Dementia and Cognitive Impairment Research
- Alzheimer's disease research and treatments
- Amyotrophic Lateral Sclerosis Research
- Mental Health and Psychiatry
- Polyomavirus and related diseases
- Neurology and Historical Studies
- Functional Brain Connectivity Studies
- Multiple Sclerosis Research Studies
- Action Observation and Synchronization
- Botulinum Toxin and Related Neurological Disorders
- Intracranial Aneurysms: Treatment and Complications
- Listeria monocytogenes in Food Safety
- Face Recognition and Perception
- Memory and Neural Mechanisms
- Herpesvirus Infections and Treatments
- Cardiovascular Health and Disease Prevention
- Neurological and metabolic disorders
- Cardiovascular Syncope and Autonomic Disorders
- Intensive Care Unit Cognitive Disorders
- Acute Ischemic Stroke Management
- Rheumatoid Arthritis Research and Therapies
- Blood Pressure and Hypertension Studies
- Neurological Disorders and Treatments
- Health, Medicine and Society
- Epilepsy research and treatment
Centre Hospitalier de Béthune
2004-2024
Allen Institute for Brain Science
2021
Institut du Cerveau
2021
Université de Lille
1994-2004
Neurological Surgery
2001
Centre Hospitalier Universitaire de Lille
1997-1999
Frontotemporal dementia (FTD) is the second cause of degenerative dementia. Behavioral changes occur before cognitive decline and remain major feature. A poor perception emotion could account for some behavioral symptoms. The aim this study was to assess in patients with FTD compare it that Alzheimer disease (AD). Fifty subjects performed tests: 20 probable AD, 18 FTD, 12 matched controls. two patient groups did not differ age, sex, severity dementia, duration disease, language tests....
Background This study reports the findings of first large-scale Phase III investigator-driven clinical trial to slow rate cognitive decline in Alzheimer disease with a dihydropyridine (DHP) calcium channel blocker, nilvadipine. Nilvadipine, licensed treat hypertension, reduces amyloid production, increases regional cerebral blood flow, and has demonstrated anti-inflammatory anti-tau activity preclinical studies, properties that could have disease-modifying effects for disease. We aimed...
Abstract Background Due to heterogeneous clinical presentation, difficult differential diagnosis with Alzheimer’s disease (AD) and psychiatric disorders, evolving criteria, the epidemiology natural history of frontotemporal lobar degeneration (FTD) remain elusive. In order better characterize FTD patients, we relied on database a regional memory clinic network standardized diagnostic procedures chose AD patients as comparator. Methods Patients that were first referred our between January...
Frontotemporal dementia (FTD) was diagnosed in 74 outpatients with a standardized assessment including neuropsychological tests, behavioural scale, structural and functional imaging. Clinical characteristics were consistent the literature data. The cohort followed for 2-6 years to determine reliable variable evaluating progression of FTD. Every fourth patient died after mean duration 7 years. At first, FTD manifests itself changes relatively stable global cognition although language, verbal...
Frontotemporal dementia (FTD) is a neurodegenerative disease characterised by behavioural disorders that suggest abnormalities of emotional processing. In previous study, we showed patients with Alzheimer's (AD) and FTD were equally able to distinguish face displaying affect from one not affect. However, recognition emotion was worse in than AD who did differ significantly controls. The aim this study follow up the perception emotions on faces these patients. poor could worsen differently...
A previous study suggested that occlusive diseases of small penetrating arteries account for most anterior choroidal artery (AChA) territory infarcts, but half the patients did not have an echocardiogram. Cases AChA infarcts associated with internal carotid stenosis or atrial fibrillation suggest this hypothesis may be wrong. The aim was to determine mechanism 16 nonselected consecutive infarcts. population consisted 8 men and women aged 17 89 years. They underwent a computed tomographic...
In our memory clinic experience, impairment differs widely in patients with frontotemporal dementia (FTD). We searched for a correlation between explicit disturbance assessed the Grober and Buschke test medial temporal atrophy on CT scan 22 consecutive FTD. Five of had lobe (MTL) atrophy. There was no significant difference two groups demographic characteristics. Free recall, cued recall learning curve were significantly better without MTL The made more intrusions. found positive total mean...
We tested the interobserver reliability of visual rating HMPAO-SPECT imaging in 271 outpatients referred to a memory clinic, and followed over 1 year. The clinical diagnoses were Alzheimer''s disease (n = 156), frontotemporal dementia 47), vascular 21), senile Lewy body type 12), anxiety/depressive disorders 14) miscellaneous 21). agreement was good (k 0.68). However, heterogeneity patterns – independent from demographic data, age at onset duration their lack sensibility specificity limited...
The identification of new nosological forms such as Lewy body disease (LBD) requires a re-evaluation the patterns observed in brain functional imaging various dementia. We studied 60 demented patients, divided into three groups and fulfilling clinical criteria for Alzheimer’s (AD), LBD frontotemporal dementia (FTD), using Tc-HMPAO brain-dedicated SPECT system. After normalisation we applied cut-off at two levels according to previously established criteria. reaffirmed already data concerning...
Background Hypertension is common among patients with Alzheimer disease. Because this group has been excluded from hypertension trials, evidence regarding safety of treatment lacking. This secondary analysis a randomized controlled trial assessed whether antihypertensive increases the prevalence orthostatic hypotension (OH) in Methods and Results Four hundred seventy-seven mild-to-moderate disease were to calcium-channel blocker nilvadipine 8 mg/day or placebo for 78 weeks. Presence OH...
Objective: Autonomy in patients with Alzheimer's disease (AD) daily life depends on the preservation of neurocognitive and motor abilities, which decline over time. So far, very few studies have investigated representations their contribution to perception cognition AD. Methods: In present study, we compared performance AD age-matched healthy participants perceptual cognitive tasks involving imagery. Experiment 1 tested explicit visual imagery through an imagined movement task. 2...
<h3>OBJECTIVES</h3> Alzheimer's disease is the most frequent cause of degenerative dementia. Despite available diagnostic criteria, improvement diagnosic accuracy still required. The aim this prospective study was to assess in a large population patients referred memory clinic value combination medial temporal lobe atrophy on oriented CT and decreased temporoparietal uptake HMPAO single photon emission tomography (SPECT). <h3>METHODS</h3> conducted 125 aged 51-93: 64 with probable (Mean (SD)...
Abstract Introduction Systemic inflammation and endothelial dysfunction are potentially modifiable factors implicated in Alzheimer’s disease (AD), which offer potential therapeutic targets to slow progression. Methods We investigated the relationship between baseline circulating levels of inflammatory (TNF-α, IL-1ß) cell markers (VCAM-1, ICAM-1, E-selectin) 18-month cognitive decline (ADAS-cog12) 266 mild-to-moderate AD patients from NILVAD study. employed individual growth models examine...